Solid tumor, adult Trials in Barcelona, Spain
Conditions / Solid tumor, adult / Barcelona, Spain
Solid tumor, adult has been the subject of sustained clinical investigation across multiple research sites.
28 total trials for this combination
Showing top 10 of 28 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | ENROLLING_BY_INVITATION | PHASE1 |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | TERMINATED | PHASE1/PHASE2 |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | COMPLETED | PHASE1 |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | COMPLETED | PHASE1/PHASE2 |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study | RECRUITING | PHASE1/PHASE2 |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT05216432 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | RECRUITING | PHASE1 |